CymaBay Builds Seladelpar Case In PBC, But Door Not Closed On NASH

The company pointed to cirrhosis benefit and less pruritis in a pooled analysis presented at EASL, which will help it will take on Intercept in primary biliary cholangitis on tolerability, cirrhosis benefit.